Chairman and Chief Executive Officer Keith Murphy is scheduled to speak at the 2015 Piper Jaffray Healthcare Conference in New York City on Wednesday, December 2, 2015 at 11:00am Eastern Time (ET).
The Latest Press Releases
A timeline of the significant events in our company’s history, from the initial research on which our company was founded to the present day.
2003 Ink-jet Printing of Viable Cells patented by Dr. Thomas Boland at Clemson University
2004–2005 Organ Printing work begun at University of Missouri–Columbia. $5M National Science Foundation Frontiers in Integrative Biological Research (FIBR) grant awarded to multi-institution team led by Prof. Gabor Forgacs of the University of Missouri–Columbia. First patent application for NovoGen™ bioprinting platform filed, Self-Assembling Cell-Aggregates and Methods of Making the Same, by Forgacs, Mironov, Jakab, Neagu.
2005–2006 Organovo founding team discusses formation of company around Forgacs organ printing technology, visits Forgacs labs in Columbia, Missouri
April 2007 Organovo, Inc. formally incorporated in Delaware, with the intent to license the Forgacs patent suite and launch a 3D bioprinting company
August 2007 Keith Murphy leaves Amgen, Inc. to begin role as full-time CEO of Organovo, Inc.
July 2008 Organovo, Inc. begins raising startup funds, leading to an eventual $3M in angel financing
November 2008 First full-time employee of Organovo, Inc. is hired
January 2009 Organovo opens laboratory in San Diego, CA
September 2009 Organovo and Invetech complete work on “Project Leeloo,” delivery of the NovoGen MMX Bioprinter™
August 2009 Organovo awarded first NIH grant, for creation of bioprinted blood vessels
December 2010 Organovo describes work on its fully cellular blood vessel, demonstrating ability to create novel tissues in 3D using only primary human cells
March 2011 Organovo begins corporate partnerships in drug discovery
February 2012 Organovo goes public through a $15.2M financing round
May 2012 Organovo expands management team
July 2012 Organovo announces two issued patents: first company patent and key founder patent
July 2012 Organovo moves to new, larger laboratory in San Diego, CA
December 2012 Organovo partners with Autodesk Research to develop 3D bioprinting software
January 2013 Organovo and OHSU Knight Cancer Institute establish collaboration for cancer research
February 2013 Organovo partners with ZenBio to create 3D tissue models
April 2013 Organovo presents data describing key features of 3D human liver model
July 2013 Organovo Stock lists on NYSE MKT
July 2013 Organovo partners with Methuselah Foundation on Funding of Bioprinting Research at Research Institutions
August 2013 Organovo closes $46.6 million secondary public offering
October 2013 Organovo reports update of 1 month performance and drug responsiveness for 3D bioprinted liver tissue
November 2013 Organovo expands headquarters facility in San Diego, CA
January 2014 Organovo announces technology access collaboration with National Institutes of Health
January 2014 Organovo announces delivery of first 3D liver tissue to Key Opinion Leader
April 2014 Organovo announces pre-release availability of 3D Liver Contract Services